Contractors / Regeneron Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

prime recipient of federal awards · UEI N3F9MH7E6HD6 ✓ from source

$326.5M

obligated · FY2023

funding agencies

100%

from Health and Hum…

states

100%

in New York

industries

Obligations by year

≈ computed

$638.4M

FY20

$5.6B

FY21

$326.5M

FY23

▼ 49%

since FY20

Where this money comes from

✓ from source

FUNDING AGENCIES

REGENERON PHARMACEUTICAL

HHS

$0.3B

Regeneron Pharmaceuticals Inc

$0.3B

FY2023 obligated

band width = obligations · FY2023 · source: USASpending.gov

Biggest awards (total value)

Production of Therapeutic in Support of National Emergency Response to Coronavirus 2019…

awarded 2021$5.6B

Total value over each award’s life, for awards active in FY2023: a decades-long contract can exceed one year’s obligations above.

What it does (NAICS / PSC)

Research and Development in Biotechnology$326.5M

Where the work lands

New York✓ from source$326.5M

Competitors

No competitors computed.

Corporate family

Single registration: no combined family.

Political contributions

Regeneron Pharmaceuticals, Inc. PAC≈ inferredgave$280.5Kto members of Congress✓ from source

Paul Tonko (Democrat)$25K

Thom Tillis (Republican)$17K

Mike Crapo (Republican)$12K

Chuck Grassley (Republican)$11.5K

Pete Aguilar (Democrat)$10K

Steve Daines (Republican)$10K

Richard E. Neal (Democrat)$10K

Charles E. Schumer (Democrat)$10K

Yvette D. Clarke (Democrat)$9K

Tim Scott (Republican)$8.5K

linked through public filings, not a claim of coordination. contribution reported to the FEC, a public campaign-finance record.

🔎

Why the labels? The graph is only worth anything if the links are trusted. Facts taken straight from a federal filing are ✓ from source; figures we calculate are ≈ computed; links we infer (corporate parents, districts, competitors, connections between records) are ≈ inferred, worded carefully, never asserted as fact and never a claim that one thing caused another. Spot an error? Tell us.